🏭AGC Enhances Biopharmaceutical Production Capacity at AGC Biologics

By bio, Pharmaceutical

🏭AGC Enhances Biopharmaceutical Production Capacity at AGC Biologics

U.S. Berkeley Plant Installs New Bioreactor to Accelerate Scale-up Applications
AGC Asahi Glass (AGC), a world-leading manufacturer of glass, chemicals and high-tech materials, has enhanced the production capacity of biopharmaceuticals at AGC Biologics (*1), AGC’s CDMO (*2) subsidiary. With this capital investment, its Berkeley Plant (California, USA) has doubled in capacity and starts full operation this March 2018.

http://www.agc.com/en/news/detail/1196810_2814.html

More from tokioX :

  1. COVID-19: AGC Biologics boosts RNA production: at its Heidelberg
  2. China’s first self-developed mRNA vaccine to enter mass production in October with annual capacity of 200 million doses
  3. Fujifilm to invest 928 million USD to expand its large scale biologics production facility in Denmark
  4. Novavax enlists AGC Biologics to manufacture adjuvant for COVID-19 shot
  5. AGC Acquires Biopharmaceutical Commercial Facility in Colorado, U.S.A.
  6. Fujifilm accelerates production of its influenza antiviral drug “Avigan® Tablet” for COVID-19.
  7. Fujifilm to Set Up iPS Cell Production Facility in U.S.